A Healthcare Technology Company

Shaping the future of non-invasive diagnostics with artificial intelligence.

main-banner-img

LIVERFASt™ has now been granted CPT Code.

LIVERFASt™, a non-invasive diagnostic tool for diagnosis, screening and monitoring patient with liver diseases.

Learn More

Why Choose us?

Fibronostics offers customized health screening tools which help with risk stratification leading to cost reduction and better management of patient population.

Fibronostics patent technology

Patent Technology

CPT Code: 0166U

Fibronostics patent technology

FDA – De Novo 510K

Fibronostics patent technology

Artifical Technology based Platform

70,000+
Patients Screened
50+
Network Health System
30+
Laboratories
900+
Medical centre & Pharmacies

Early Disease Intervention

Non-invasive serum biomakers platform for the assistance of diagnosis, screening and monitoring of chronic conditions across multiple organs.

1

Diagnosis

Non-invasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.

2

Screening

Risk stratification among large patient populations allows for better management leading to cost reductions.

3

Monitoring

Regular surveillance with easily repeatable non-invasive diagnostics enables optimized disease management.

Non-invasive solutions for diagnosis, screening and monitoring.

X

Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors

Learn more